Company news
Cloudbreak Pharma, Inc. (HKEX:2592) news
Cloudbreak Pharma, Inc. news releases on 6ix. Latest, Sep 30, 2026: FORMATION OF AN INDEPENDENT SPECIAL COMMITTEE; DELAY IN PUBLICATION AND DESPATCH…
Press releases & updates
FORMATION OF AN INDEPENDENT SPECIAL COMMITTEE; DELAY IN PUBLICATION AND DESPATCH OF 2026 INTERIM REPORT; AND CONTINUED SUSPENSION OF TRADING
September 30, 2026
Cloudbreak Pharma Announces Results of First-of-Its-Kind Patient Survey on Pinguecula, Confirming Significant Unmet Need and Impact on Quality of Life
June 22, 2026
Cloudbreak Pharma Announces Final Patient Visit for 12-Month Efficacy Endpoint in Phase 3 Study of CBT-001 as a Potential Treatment for Pterygium
June 4, 2026
Cloudbreak Pharma to Present at the Stifel 2026 Virtual Ophthalmology Forum
May 12, 2026
Cloudbreak Pharma Announces Presentation on its Multi-Kinase Inhibition (MKI) Platform and Ongoing Clinical Programs at Eyecelerator @ ARVO 2026
April 22, 2026
Cloudbreak Pharma Announces Launch of Cloudbreakpharma.com to Raise Awareness of its Pipeline of Novel First-in-Class Therapeutics to Treat Serious Underserved Ophthalmic Diseases
April 9, 2026
Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004
January 27, 2026
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
July 20, 2025